NASDAQ:IOVA

Iovance Biotherapeutics Stock Predictions

Healthcare > Biotechnology

Buy IOVA

*Your capital is at risk

$3.79

-0.310 (-7.56%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

IOVA Prediction Chart

IOVA Predictions History

Latest community submissions for IOVA.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
JS Pro	Dec 29, 2020	$47.86 +0.53%	$47.61	X	99.47%	4
Andy Jackson @AndyJackson.184174	Dec 29, 2020	Bullish	$47.61	X	—	0
GoldenNugget Pro	May 7, 2019	$11.35 +3.05%	$11.01	X	96.95%	0
GoldenNugget Pro	May 6, 2019	$10.86 -5.26%	$11.46	X	94.74%	0
NameNotImportant Pro	May 3, 2019	$10.71 -5.97%	$11.39	X	94.03%	0
NameNotImportant Pro	Apr 24, 2019	$11.41 +4.78%	$10.89	X	95.23%	0
Nicki.Kim.16469	Apr 9, 2018	$13.93 -3.60%	$14.45	X	96.40%	0
Puspendu.Banerjee.20499	Feb 27, 2018	$18.50 +6.02%	$17.45	X	94.00%	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for IOVA with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT IOVANCE BIOTHERAPEUTICS, INC.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or pers...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by